About PanTher Therapeutics
PanTher Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2014. Drug delivery systems for inoperable solid tumors are developed. It operates on a HealthTech model. PanTher Therapeutics has raised $15.35 million across 10 funding rounds from investors including CHV, Angel Physicians Fund and state.tx.us. The company has 47 employees. PanTher Therapeutics offers products and services including PTM-101 and Sagittari Platform. Its focus areas include Biotechnology and Oncology. Its legal entity is PanTher Therapeutics, Inc. Its competitors include Tonix Pharma, Zyl Therapeutics and Sun BioPharma; 3 of its 3 listed competitors have raised funding.
Company details
PanTher Therapeutics is engaged in developing advanced cancer treatments through its proprietary Sagittari platform. The company specializes in long-lasting, high-dose local chemotherapeutic solutions for oncology, targeting tumors with minimal systemic exposure. Its lead product, PTM-101, is under clinical development for pancreatic cancer. The platform is utilized to engineer drug products for optimal dose and duration, integrated with interventional oncology procedures. Pipeline opportunities are also being explored to expand therapeutic applications in the healthcare sector.
- Headquarters Cambridge, United States
- Employees 47
- SectorsHealthcare
- Email••••••••
- Website panthertx.com
- Social LinkedIn X
- Legal Name Panther Therapeutics, Inc
- Total Equity Funding$15.35M (USD)
in 10 rounds
- Latest Funding Round$3.02M (USD), Series B
Mar 2025
- InvestorsCHV
& 2 more
- Employee Count47
Products & Services of PanTher Therapeutics
PanTher Therapeutics offers a comprehensive portfolio of products and services, including PTM-101 and Sagittari Platform.
A chemotherapy patch for pancreatic cancer treatment developed.
Platform for creating optimized cancer drug delivery systems.
Funding Insights of PanTher Therapeutics
PanTher Therapeutics has successfully raised a total of $15.35M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $3.02 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.35M
- Total Rounds 10
- Last Round Series B — $3.02M
- First Round $95,000
(Jun 2015)
- Investors Count 3
All 10 funding rounds of PanTher Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2025 | $3.02M | Series B | – | – | – |
| Nov 2023 | $2.68M | Series A | – | – | – |
| Dec 2022 | $1.26M | Series A | – | – | – |
| Aug 2022 | $14.2M | Grant | – | – | |
| Jun 2022 | $1.06M | Series A | – | – | – |
| Jun 2021 | $7.33M | Series A | – | CHV | |
| Jun 2019 | $209,488 | Debt – Conventional | – | – | – |
| Aug 2018 | $268,061 | Debt – Conventional | – | – | – |
| Nov 2016 | $35,000 | Debt – Conventional | – | – | – |
| Jun 2015 | $95,000 | Debt – Conventional | – | – | – |
3 investors in total: 3 institutional.
Investors in PanTher Therapeutics
PanTher Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include CHV, Angel Physicians Fund and state.tx.us.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| chv.vc | ||||
Investment and advisory services are provided to healthcare startups. | angelphysicians.com | |||
| state.tx.us |
Investor details for PanTher Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PanTher Therapeutics
19 people are tracked at PanTher Therapeutics (5 in leadership, 10 in board & advisors, 4 in team); the tracked headcount is 47.
| Name | Role | Group |
|---|---|---|
Margaret Lashof-Sullivan | Director of Research and Development | Leadership |
Sara (Vestecka) Fanning | Senior Director, Business Operations And Finance | Leadership |
Laura Indolfi | Co-Founder & CEO | Leadership |
David Mackey | COO | Leadership |
Meg Lashof-Sullivan | Director of R&D | Leadership |
Jason Fleming | Clinical Advisor | Board & advisors |
Maria Palasis | Director | Board & advisors |
Elazer Edelman | Scientific Co-Founder | Board & advisors |
Thomas E. Clancy | Clinical Advisor | Board & advisors |
David Ting | Scientific Co-Founder | Board & advisors |
Timothy B. Gardner | Clinical Advisor | Board & advisors |
Theodore Hong | Clinical Advisor | Board & advisors |
Darshana Zaveri | Director | Board & advisors |
Manish Bhandari | Director | Board & advisors |
Dan Wildman | Strategic Advisor | Board & advisors |
Tucker Folsom | Associate Scientist | Team |
Chris Johnson | Scientist | Team |
Maya Mundelboim | Research Associate | Team |
Cecilia Castillo | Executive Assistant | Team |
Complete people profiles for PanTher Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PanTher Therapeutics
3 dated milestones of PanTher Therapeutics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded PanTher Therapeutics is founded.
- Funding First funding round of $95K.
- Funding Latest funding round, Series B, of $3.0M.
Competitors of PanTher Therapeutics
PanTher Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Tonix Pharma, Zyl Therapeutics and Sun BioPharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tonixpharma.com | 2007 | New York, United States | $4.45M | 117 | Next-generation medicines for CNS and immunological disorders are developed. | |
| zylotherapeutics.com | 2017 | Greenville, United States | $9.43M | Hydrogel-derived nanoparticles for topical drug delivery are developed. | ||
| sunbiopharma.com | 2011 | Ponte Vedra Beach, United States | $4.05M | 4 | Therapeutics for pancreatic cancer and pancreatitis are developed. |
Detailed competitors of PanTher Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PanTher Therapeutics
The website of PanTher Therapeutics (panthertx.com) receives about 1K visits a month.
- Monthly visits1K
▼ 26.6% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as PanTher Therapeutics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Panther Therapeutics
Complete news archive for PanTher Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PanTher Therapeutics
PanTher Therapeutics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
PanTher Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
PanTher Therapeutics is a funded company, having raised a total of $15.35M across 10 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $95K, raised on Jun 2015.
PanTher Therapeutics has 47 employees.
PanTher Therapeutics is engaged in developing advanced cancer treatments through its proprietary Sagittari platform. The company specializes in long-lasting, high-dose local chemotherapeutic solutions for oncology, targeting tumors with minimal systemic exposure. Its lead product, PTM-101, is under clinical development for pancreatic cancer. The platform is utilized to engineer drug products for optimal dose and duration, integrated with interventional oncology procedures. Pipeline opportunities are also being explored to expand therapeutic applications in the healthcare sector.
PanTher Therapeutics's top competitors include Tonix Pharma, Sun BioPharma and Zyl Therapeutics.
PanTher Therapeutics offers PTM-101 and Sagittari Platform.
PanTher Therapeutics has 3 investors. Key investors include CHV, Angel Physicians Fund, and state.tx.us.
PanTher Therapeutics operates through Panther Therapeutics, Inc.